{
  "docId": "019de074-6c10-759a-a503-c8b869115e9a",
  "docSlug": "3f9321c37d26dde2e5a75b53f195ef9c",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 31 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 31,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "The table displays projected royalties and milestones for 2023-2026. The slide highlights the transition of royalty payments back to Theravance Biopharma starting in 2029.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-6c10-759a-a503-c8b869115e9a/18",
  "deckHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a",
  "deckJsonHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json",
  "deckAnchorHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.6,
        "y": 0.42
      },
      "kind": "list",
      "text": "Ex-US royalties return Jul. 1, 2029; US royalties return after Jan. 1, 2031; Paid directly from Royalty Pharma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67e477f2-c9e5-433b-8998-11b3210e4392",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.04,
        "y": 0.8
      },
      "kind": "metric",
      "text": "Q4 Net Sales of $537M | FY 2022 Net Sales of $2.1B",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6994aad-d584-4506-8c98-63f1c01592ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.14,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. If both milestones are achieved in a given year... 4. Source: Bloomberg",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01d46c1e-51b2-4563-b978-76662af1c0e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "subtitle",
      "text": "GSK's TRELEGY ELLIPTA (FF/UMEC/VI): First and only once-daily single inhaler triple therapy",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e4f477e-4f1e-4afc-b25b-d860ebb5b5ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.42,
        "w": 0.38,
        "x": 0.09,
        "y": 0.385
      },
      "kind": "table",
      "text": "Year, Royalties, Global Net Sales Equivalent, Milestone table for 2023-2026",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cd1c2cd-2b31-4bec-aa8c-a3d1be7cc729",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "TRELEGY ELLIPTA Milestones and Royalties",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed56179d-0264-4b54-9969-374046368be3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "81994016-c8c7-465d-a43d-88fe3948a979",
      "evidence": "table/data: Year, Royalties, Global Net Sales Equivalent, Milestone table for 2023-2026",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 19,
      "from": 6,
      "beatId": "d5542c65-e352-4522-bba8-062503c55e06",
      "arcName": "The Transformation Tale",
      "arcSlug": "transformation-tale",
      "beatName": "Future Vision (Gain)",
      "beatSlug": "transformation-tale-future-vision-gain",
      "evidence": "Slides 6-19 present the company's vision and growth opportunities",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}